2021 American Transplant Congress
AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates
*Purpose: Immune intervention with a CD40L specific monoclonal antibody (mAb, Hu5c8, Biogen) has previously been shown to safely and effectively prevent islet allograft (IA) rejection…2021 American Transplant Congress
Impact of Bacterial Infection on HLA Allosensitization Among Kidney Recipients on the Waitlist
*Purpose: The clinical relevance of HLA allosensitization associated with bacterial infection remains poorly defined. The primary objective of this study is to determine the incidence,…2020 American Transplant Congress
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations
1Plexision, Pittsburgh, PA, 2Bristol-Myers-Squibb, Princeton, NJ
*Purpose: Background: Kidney recipients treated with the T-cell costimulation blocker, belatacept, experience a higher incidence of acute cellular rejection (ACR) and lower incidence of donor-specific…2020 American Transplant Congress
Treatment Strategies to Suppress Donor Specific Antibodies: Highlights from a Decade of Research Experience in a Mouse Model of Allo-Sensitization
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Difficulty in desensitization in highly sensitized patients remain problematic in organ transplantation. For over 12 years, our laboratory has been carrying out an HLA…2020 American Transplant Congress
Desensitization for Deceased Donor Transplantation: Testing a New Paradigm in the Nonhuman Primate
*Purpose: Desensitization regimens have rarely been applied to deceased donor allotransplantation. We hypothesized that belatacept monotherapy during a simulated deceased donor waiting list period would…2020 American Transplant Congress
Blocking Complement Component C3 in a Sensitized Nonhuman Primate Model of Kidney Allotransplantation
*Purpose: Sensitized transplant recipients represent a challenge due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection. Complement inhibition has…2020 American Transplant Congress
Novel Role of Qa-1, a Murine Homolog of HLA-E, in Controlling Follicular Helper T Cells During Humoral Alloimmunity
*Purpose: Antibody-mediated rejection (AMR) is a major challenge in prolonging allograft survival. Limited insight into the humoral alloimmunity hinders the development of therapeutic strategies. We…2020 American Transplant Congress
De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival
*Purpose: To determine the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function.*Methods: A single-center review…2020 American Transplant Congress
Activated Circulating Memory T Follicular Helper Cells with Self-Renewal Potential Underlie the Kidney Allograft Antibody-Mediated Rejection Response
1Surgery, University of Pittsburgh, Pittsburgh, PA, 2Inserm UMR 976, Paris, France
*Purpose: Antibody-mediated rejection (ABMR) is the leading cause of allograft failure after organ transplantation. Yet, the cellular events that lead to the induction of a…2020 American Transplant Congress
Estimating Alloantibody Levels in Highly-Sensitized Renal Allograft Candidates Using Serial Dilutions
1Northwestern University, Chicago, IL, 2Mayo Clinic, Rochester, MN
*Purpose: Despite the new Kidney Allocation System and Kidney Paired Donation, renal allograft candidates with a >99.9% cPRA still have extremely low rates of transplantation…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 40
- Next Page »